Effect of Huangqi Yijiang decoction combined with FOLFOX6 chemotherapy on immune function and quality of life in patients with Qi-deficiency and heat-toxin type after colorectal cancer surgery

doi:10.3877/cma.j.issn.2095-2015.2025.05.002

Abstract

Abstract:

Objective

To investigate the effect of Huangqi Yijiang decoction combined with FOLFOX6 chemotherapy on immune function and quality of life in patients with Qi-deficiency and heat-toxin type after colorectal cancer surgery.

Methods

A total of 134 patients who underwent laparoscopic radical resection for colorectal cancer and received adjuvant chemotherapy at the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from September 2022 to December 2024 were prospectively selected as the research objects. According to the random number table method, they were divided into conventional group (FOLFOX6+conventional treatment) and treatment group (FOLFOX6+Huangqi Yijiang decoction), with 67 cases in each group. The TCM syndrome score, CD4⁺, CD8⁺, carcino-embryonic antigen (CEA), carbohydrate antigen (CA)19-9, CA72-4 levels and KPS score before and after treatment were compared between the two groups.

Results

After 6 treatment courses (14 days per course), compared with the conventional group, the TCM syndrome score and serum CEA, CA199 and CA724 levels in the treatment group were decreased (all P<0.05). Compared with the conventional group, CD4⁺, CD4⁺/CD8⁺ ratio and KPS score were increased, CD8⁺ cell level and the incidence and severity of nausea, vomiting and diarrhea were decreased in the treatment group (all P<0.05).

Conclusion

Huangqi Yijiang decoction combined with FOLFOX6 regimen can effectively improve the immune function and quality of life of patients with Qi-deficiency and heat-toxin after colorectal cancer surgery, and reduce adverse reactions of chemotherapy.

Key words: Colorectal cancer, Huangqi Yijiang decoction, Adjuvant chemotherapy, Qi-deficiency and heat-toxin type

Mengxin Zhang, Min Wang, Jiaqian Zhang, Meimei Ren, Xueyan Jia. Effect of Huangqi Yijiang decoction combined with FOLFOX6 chemotherapy on immune function and quality of life in patients with Qi-deficiency and heat-toxin type after colorectal cancer surgery[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(05): 426-430.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.05.002

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I05/426

Figures/Tables 6

References 24

[1]	Li J, Ma X, Chakravarti D, et al. Genetic and biological hallmarks of colorectal cancer[J]. Genes Dev, 2021, 35(11-12): 787-820.
[2]	Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review[J]. JAMA, 2021, 325(7): 669-685.
[3]	Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009.
[4]	Patel SG, Karlitz JJ, Yen T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 262-274.
[5]	孔凡铭, 王娜, 谢红霞, 等. 消岩汤联合卡培他滨和贝伐珠单抗在结直肠癌维持治疗中的临床研究[J]. 中国肿瘤临床, 2023, 50(10): 519-525.
[6]	叶子玉, 宋程, 唐蔚, 等. 基于"虚气留滞"理论探讨益气调腑汤治疗晚期结直肠癌脾虚气滞型患者的回顾性研究[J]. 湖南中医药大学学报, 2025, 45(2): 363-369.
[7]	陈秋谷, 吴锦如, 李常慧, 等. HPLC-MS/MS法同时测定黄芪桂枝五物汤中21种成分的含量[J]. 中成药, 2025, 47(2): 365-371.
[8]	林家冉, 苟筱雯, 赵林华, 等. 态靶辨证在脾虚湿瘀型慢性胃炎中的运用——黄芪建中汤加蒲公英、白及、生薏苡仁[J]. 辽宁中医杂志, 2021, 48(1): 1-4.
[9]	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2023版)[J]. 中华消化外科杂志, 2023, 22(6): 667-698.
[10]	林洪生, 刘杰, 张英. 《恶性肿瘤中医诊疗指南》的内涵及其意义[J]. 中国肿瘤临床与康复, 2016, 23(3): 257-260.
[11]	梁茂新, 高天舒. 《中药新药临床研究指导原则》脏腑诸证考察与分析[J]. 中国中医基础医学杂志, 2008, 14(5): 330-331, 342.
[12]	Mahmoud NN. Colorectal Cancer: Preoperative Evaluation and Staging[J]. Surg Oncol Clin N Am, 2022, 31(2): 127-141.
[13]	Kluetz PG, Chingos DT, Basch EM, et al. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)[J]. Am Soc Clin Oncol Educ Book, 2016, 35(1): 67-73.
[14]	Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target[J]. Mol Cancer, 2022, 21(1): 144.
[15]	张冰凯, 刘炳玉, 崔玉峰. 中医扶正培本辅助腹腔镜结直肠癌手术对老年患者免疫功能的影响[J]. 辽宁中医杂志, 2024, 51(6): 100-103.
[16]	彭永焕. 黄芪苡酱汤联合FOLFOX+贝伐珠单抗治疗转移性结直肠癌患者的临床研究[D]. 重庆: 重庆医科大学, 2024.
[17]	杜利莉, 王钢, 梁研, 等. 黄芪-莪术-重楼配伍调控巨噬细胞极化对结直肠癌细胞增殖、迁移影响[J]. 南京中医药大学学报, 2024, 40(2): 137-144.
[18]	韩珊珊, 路洋, 刘寨东. 薏苡仁化学成分及抗肿瘤作用研究进展[J]. 中华中医药学刊, 2024, 42(9): 210-219.
[19]	Fan A, Wang B, Wang X, et al. Immunotherapy in colorectal cancer: current achievements and future perspective[J]. Int J Biol Sci, 2021, 17(14): 3837-3849.
[20]	董晓茜, 董笑博, 高雪, 等. 基于"扶正祛邪"探讨黄芪苦参配伍改善结肠癌荷瘤小鼠肿瘤免疫微环境作用机制[J]. 辽宁中医药大学学报, 2025, 27(2): 7-12.
[21]	Li L, Lin X, Wang L, et al. Immuno-PET of colorectal cancer with a CEA-targeted[68 Ga]Ga-nanobody: from bench to bedside[J]. Eur J Nucl Med Mol Imaging, 2023, 50(12): 3735-3749.
[22]	Ding Q, Sun Y, Zhang J, et al. Utility and specificity of plasma heat shock protein 90 alpha, CEA, and CA199 as the diagnostic test in colorectal cancer liver metastasis[J]. J Gastrointest Oncol, 2022, 13(5): 2497-2504.
[23]	蒲丹, 龙煊, 周玉龙, 等. 血清外泌体miR-224对结直肠癌肝转移患者射频消融治疗后复发的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(1): 45-52.
[24]	高静, 夏婷婷. 血清乳酸脱氢酶、中性粒细胞/淋巴细胞比值、血浆纤维蛋白原/前白蛋白比值对晚期结直肠癌患者姑息化疗效果与不良反应的评价[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(3): 203-207.

临床资料	常规组(n=67)	治疗组(n=67)	t/χ²	P
年龄(岁,±s)	57.37±4.18	56.97±5.04	0.503	0.616
性别[例(%)]
男	34(50.75)	36(53.73)	0.120	0.729
女	33(49.25)	31(46.27)	0.120	0.729
体重指数(kg/m²,±s)	22.14±2.16	22.01±1.92	0.369	0.713
手术时间(min,±s)	158.2 8±15.62	160.28±17.09	0.707	0.481
麻醉时长(min,±s)	191.27±20.12	189.39±19.46	0.550	0.583
术中出血量(mL,±s)	92.69±20.37	89.57±18.96	0.917	0.361
TNM分期[例(%)]
Ⅱ	38(56.72)	36(53.73)	0.121	0.728
Ⅲ	29(43.28)	31(46.27)	0.121	0.728
肿瘤分化程度[例(%)]
高分化	23(34.33)	26(38.80)	0.448	0.799
中分化	35(52.24)	34(50.75)
低分化	9(13.43)	7(10.45)

临床资料	常规组(n=67)	治疗组(n=67)	t/χ²	P
年龄(岁,±s)	57.37±4.18	56.97±5.04	0.503	0.616
性别[例(%)]
男	34(50.75)	36(53.73)	0.120	0.729
女	33(49.25)	31(46.27)	0.120	0.729
体重指数(kg/m²,±s)	22.14±2.16	22.01±1.92	0.369	0.713
手术时间(min,±s)	158.2 8±15.62	160.28±17.09	0.707	0.481
麻醉时长(min,±s)	191.27±20.12	189.39±19.46	0.550	0.583
术中出血量(mL,±s)	92.69±20.37	89.57±18.96	0.917	0.361
TNM分期[例(%)]
Ⅱ	38(56.72)	36(53.73)	0.121	0.728
Ⅲ	29(43.28)	31(46.27)	0.121	0.728
肿瘤分化程度[例(%)]
高分化	23(34.33)	26(38.80)	0.448	0.799
中分化	35(52.24)	34(50.75)
低分化	9(13.43)	7(10.45)

中医证候		常规组(n=67)	治疗组(n=67)	Z	P
乏力	治疗前	2(1,3)	2(1,3)	0.748	0.455
乏力	治疗后	1(0,2)^*	1(0,2)^*	4.126	<0.001
气短	治疗前	2(1,3)	2(1,3)	0.694	0.487
气短	治疗后	1(0,3)^*	1(0,2)^*	3.425	<0.001
食欲减退	治疗前	2(1,3)	2(1,3)	0.489	0.625
食欲减退	治疗后	2(0,3)^*	1(0,2)^*	2.604	0.009
便秘	治疗前	1(0,2)	1(0,3)	0.243	0.808
便秘	治疗后	1(0,2)^*	1(0,1)^*	2.370	0.018
大便脓血	治疗前	1(0,2)	1(0,2)	0.312	0.755
大便脓血	治疗后	0(0,2)^*	0(0,1)^*	2.734	0.006
腹部隐痛	治疗前	2(0,3)	2(0,3)	0.448	0.654
腹部隐痛	治疗后	1(0,2)^*	0(0,2)^*	3.593	<0.001
口苦	治疗前	2(1,3)	2(1,3)	0.741	0.459
口苦	治疗后	1(0,2)^*	1(0,2)^*	3.584	<0.001
身热	治疗前	1(0,2)	1(0,2)	1.236	0.216
身热	治疗后	0(0,2)^*	0(0,1)^*	1.983	0.047
尿赤	治疗前	2(1,3)	2(1,3)	0.681	0.496
尿赤	治疗后	1(0,2)^*	0(0,2)^*	3.692	<0.001

中医证候		常规组(n=67)	治疗组(n=67)	Z	P
乏力	治疗前	2(1,3)	2(1,3)	0.748	0.455
乏力	治疗后	1(0,2)^*	1(0,2)^*	4.126	<0.001
气短	治疗前	2(1,3)	2(1,3)	0.694	0.487
气短	治疗后	1(0,3)^*	1(0,2)^*	3.425	<0.001
食欲减退	治疗前	2(1,3)	2(1,3)	0.489	0.625
食欲减退	治疗后	2(0,3)^*	1(0,2)^*	2.604	0.009
便秘	治疗前	1(0,2)	1(0,3)	0.243	0.808
便秘	治疗后	1(0,2)^*	1(0,1)^*	2.370	0.018
大便脓血	治疗前	1(0,2)	1(0,2)	0.312	0.755
大便脓血	治疗后	0(0,2)^*	0(0,1)^*	2.734	0.006
腹部隐痛	治疗前	2(0,3)	2(0,3)	0.448	0.654
腹部隐痛	治疗后	1(0,2)^*	0(0,2)^*	3.593	<0.001
口苦	治疗前	2(1,3)	2(1,3)	0.741	0.459
口苦	治疗后	1(0,2)^*	1(0,2)^*	3.584	<0.001
身热	治疗前	1(0,2)	1(0,2)	1.236	0.216
身热	治疗后	0(0,2)^*	0(0,1)^*	1.983	0.047
尿赤	治疗前	2(1,3)	2(1,3)	0.681	0.496
尿赤	治疗后	1(0,2)^*	0(0,2)^*	3.692	<0.001

T淋巴细胞亚群		常规组(n=67)	治疗组(n=67)	t	P
CD4⁺(%)	治疗前	36.68±6.72	37.02±5.65	0.319	0.750
CD4⁺(%)	治疗后	40.12±6.41^*	44.16±5.83^*	3.818	<0.001
CD8⁺(%)	治疗前	31.05±3.44	30.94±4.01	0.170	0.865
CD8⁺(%)	治疗后	28.51±3.15^*	24.93±3.24^*	6.485	<0.001
CD4⁺/CD8⁺	治疗前	1.17±0.09	1.21±0.22	1.405	0.164
CD4⁺/CD8⁺	治疗后	1.40±0.08^*	1.80±0.30^*	10.389	<0.001

Please choose a citation manager

Content to export